Atika Capital Management’s Sarepta Therapeutics SRPT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q1
Sell
-59,100
Closed -$10.1M 123
2020
Q4
$10.1M Buy
59,100
+5,100
+9% +$756K 0.79% 60
2020
Q3
$7.58M Sell
54,000
-6,000
-10% -$912K 0.62% 53
2020
Q2
$9.62M Buy
60,000
+8,600
+17% +$1.17M 1.24% 29
2020
Q1
$5.03M Sell
51,400
-20,600
-29% -$2.35M 0.96% 33
2019
Q4
$9.29M Buy
+72,000
New +$7.27M 1.79% 17
2019
Q3
Sell
-92,000
Closed -$14M 87
2019
Q2
$14M Buy
92,000
+2,000
+2% +$243K 2.75% 5
2019
Q1
$10.7M Buy
90,000
+11,900
+15% +$1.53M 2.18% 9
2018
Q4
$8.52M Sell
78,100
-900
-1% -$113K 2.51% 11
2018
Q3
$12.8M Buy
79,000
+7,000
+10% +$957K 2.29% 7
2018
Q2
$9.52M Sell
72,000
-25,000
-26% -$2.36M 1.83% 9
2018
Q1
$7.19M Buy
97,000
+5,000
+5% +$333K 2.46% 11
2017
Q4
$5.12M Sell
92,000
-8,000
-8% -$424K 1.98% 18
2017
Q3
$4.54M Buy
+100,000
New +$4M 1.3% 18

Other funds holding SRPT

Atika Capital Management's SRPT Position: Q1 2021 in Review

Atika Capital Management sold out of Sarepta Therapeutics (SRPT) in Q1 2021, closing a stake of 59,100 shares — an estimated $10.1M sold.

Atika Capital Management first reported a position in SRPT in Q3 2017 and held it in 13 quarters. The position peaked at $14M in Q2 2019. 366 funds tracked by Wall St. Rank hold SRPT as of Q1 2021.

  • Atika Capital Management reported no remaining Sarepta Therapeutics position as of Q1 2021 after selling out during the quarter.
  • Atika Capital Management sold 59,100 Sarepta Therapeutics shares in Q1 2021, an estimated $10.1M.
  • Atika Capital Management first reported a position in Sarepta Therapeutics in Q3 2017 and held it in 13 quarters.
  • Atika Capital Management's Sarepta Therapeutics position peaked at $14M in Q2 2019.
  • 366 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q1 2021.

Based on Atika Capital Management's 13F filing for Q1 2021, filed 14 May 2021.